Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Becton, Dickinson and Company before investing.

In this article, we go over a few key elements for understanding Becton, Dickinson and Company’s stock price such as:

• Becton, Dickinson and Company’s current stock price and volume
• Why Becton, Dickinson and Company’s stock price changed recently
• Upgrades and downgrades for BDX from analysts
• BDX’s stock price momentum as measured by its relative strength

About Becton, Dickinson and Company (BDX)

Before we jump into Becton, Dickinson and Company’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Want to learn more about Becton, Dickinson and Company’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Becton, Dickinson and Company.

What Caused Becton, Dickinson and Company Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 30, 2025, there were 0 analysts who downgraded Becton, Dickinson and Company’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Becton, Dickinson and Company’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Becton, Dickinson and Company’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Becton, Dickinson and Company’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Becton, Dickinson and Company (BDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Becton, Dickinson and Company

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 30, 2025, Becton, Dickinson and Company has a weighted four-quarter relative price strength of -5.77%, which translates to a Momentum Score of 38 and is considered to be Weak.

Want to learn more about how Becton, Dickinson and Company is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Becton, Dickinson and Company Stock Price: Bottom Line

As of May 1, 2025, Becton, Dickinson and Company’s stock price is $176.980, which is down 14.54% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Becton, Dickinson and Company stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.